We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:50773
Name paraganglioma
Definition A pheochromocytoma that arises in extraadrenal sympathetic ganglia.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation benign neoplasm organ system benign neoplasm endocrine organ benign neoplasm pheochromocytoma paraganglioma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00843037 Phase II Sunitinib Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NLD | CAN 0
NCT01371201 Phase II Sunitinib First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPPP) Completed NLD | ITA | FRA | DEU 0
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT01838187 Expanded access Vorinostat Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma No longer available USA 0
NCT01967576 Phase II Axitinib Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Completed USA 0
NCT02302833 Phase I Cabozantinib Cabozantinib for Malignant Pheochromocytoma Completed USA 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT02834013 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT03008369 Phase II Lenvatinib Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Completed USA 0
NCT03165721 Phase II Guadecitabine A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Terminated USA 0
NCT03839498 Phase II Axitinib Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma Active, not recruiting USA 0
NCT04106843 Phase II lutetium Lu 177 dotatate Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Withdrawn USA 0
NCT04187404 Phase Ib/II EO2401 + Nivolumab A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (Spencer) Terminated USA | SWE | NLD | ITA | FRA | ESP | DNK | DEU 0
NCT04394858 Phase II Olaparib + Temozolomide Temozolomide Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer Recruiting USA 0
NCT04400474 Phase II Atezolizumab + Cabozantinib Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) Active, not recruiting ESP 0
NCT04614766 Phase Ib/II 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) Withdrawn USA 0
NCT04924075 Phase II Belzutifan Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015) Recruiting USA | TUR | SWE | NOR | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS 6
NCT05142241 Phase II Talazoparib + Temozolomide Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study Suspended USA 0
NCT06427798 Phase Ib/II 212Pb-VMT-alpha-NET Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy Recruiting USA 0
NCT06479811 Phase I 212Pb-VMT-alpha-NET [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers Not yet recruiting USA 0